Numab Therapeutics AG Revenue and Competitors
Estimated Revenue & Valuation
- Numab Therapeutics AG's estimated annual revenue is currently $14.7M per year.
- Numab Therapeutics AG's estimated revenue per employee is $155,000
Employee Data
- Numab Therapeutics AG has 95 Employees.
- Numab Therapeutics AG grew their employee count by 9% last year.
Numab Therapeutics AG's People
| Name | Title | Email/Phone |
|---|
Numab Therapeutics AG Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Numab Therapeutics AG?
Numab Therapeutics is an oncology-focused biopharmaceutical company based in the Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCHâ„¢ technology platform we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. Our lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes.
keywords:N/A
N/A
Total Funding
95
Number of Employees
$14.7M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Numab Therapeutics AG News
Numab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. At Numab, we are writing the next chapter...